Poolbeg Pharma PLC Announces Capital Markets Day
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announced a Capital Markets Day scheduled for November 30, 2022, focusing on its growing pipeline in infectious disease vaccines and treatments, alongside innovative AI programs.
CEO Jeremy Skillington will host the event with insights into the infectious disease market, projected to exceed $250 billion by 2025. Notable speakers include AI leaders and clinical experts. A live webcast will be available for retail investors. Following the event, a recording will be accessible on the company's website.
- Capital Markets Day scheduled for November 30, 2022, indicating proactive investor engagement.
- Focus on innovative infectious disease vaccines and treatments, enhancing growth potential.
- Expected insights into AI programs that leverage data from human challenge trials.
- Market opportunity highlighted with the infectious disease sector projected to exceed $250 billion by 2025.
- None.
LONDON, UK / ACCESSWIRE / November 17, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10 am - 12:45 pm.
The event, which will be chaired by Jeremy Skillington, Chief Executive Officer, will provide insights into a number of the Company's growing pipeline of infectious disease vaccines and treatments and one of its innovative artificial intelligence programmes which is unlocking the power of human challenge trial data. In addition, attendees will gain a greater understanding of how Poolbeg's unique model and business development strategy can drive growth from the infectious disease market. A networking lunch will follow at the end of the session.
There will be an opportunity for attendees to take part in a Q&A with Poolbeg's management team including Ian O'Connell, Chief Financial Officer and David English, VP of Business Development as well as a number of guest speakers:
• | Dr Tal Almog of CytoReason, one of Poolbeg's artificial intelligence partners; a world leader in AI which to date has worked with five of the world's top ten pharma companies |
• | Derek Gilroy, Head of the Centre for Clinical Pharmacology and Professor of Immunology at University College London and has pioneered research examining the molecular and biochemical pathways that regulates the resolution of acute immune reactions |
• | Professor Brendan Buckley, co-founder of Minerva Medical, acquired by IQVIA and Firecrest Clinical, acquired by ICON plc where he held the position of Chief Medical Officer. Brendan has over thirty years of experience in clinical research and has published over 150 scientific papers |
• | Further speakers will be announced in advance of the event |
Analysts, institutional investors and media are welcome to attend the event in the City of London. Due to restrictions on numbers, it will not be possible for all interested parties to attend in-person. However, a live webcast will be available for retail investors and others to view the presentations here.
To register your interest to attend the in-person event, please RSVP to poolbeg@instinctif.com.
A recording of the presentation will be made available on the Company's website after the event here.
- Ends -
Enquiries
Poolbeg Pharma Plc | +44 (0) 207 183 1499 |
finnCap Ltd (Nominated Adviser & Joint Broker) | +44 (0) 207 220 0500 |
Singer Capital Markets (Joint Broker) | +44 (0) 207 496 3000 |
J&E Davy (Joint Broker) | +353 (0) 1 679 6363 |
Instinctif Partners | +44 (0) 20 7457 2020 |
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to license or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed
With its initial assets from hVIVO plc (formerly named Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with outputs from the first programme expected by year end 2022.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Poolbeg Pharma PLC
View source version on accesswire.com:
https://www.accesswire.com/726439/Poolbeg-Pharma-PLC-Announces-Capital-Markets-Day
FAQ
What is the date of Poolbeg Pharma's Capital Markets Day?
What will be discussed at the Capital Markets Day for POLBF?
Who will host the Capital Markets Day event for Poolbeg Pharma?
How can investors attend Poolbeg Pharma's Capital Markets Day?
What is the significance of the infectious disease market for Poolbeg Pharma?
